Light yellow to yellow crystalline powder or powder
Melting Point:
136-140°C
Long-Term Storage:
Store long-term at -20°C
BIOLOGICAL INFO
Application(s):
Antineoplastic Agent; Protein Kinase Inhibitor
Form:
Free base
REVIEW A dual tyrosine kinase inhibitor which interrupts the HER2/neu (ErbB-2) and epidermal growth factor receptor (EGFR) pathways
REFERENCES
[1]
Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O''Shaughnessy J (2012). Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 30(21):2585-92. PMID 22689807.
[2]
Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ (2012). The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 23(6):1455-64. PMID 21989330.
Add to Favorites 
Delete from Favorites 
